Trending
- Chidamide‑augmented BEAM conditioning and maintenance in first-remission T‑cell lymphoma: a single‑arm phase 2 experience
- Overall survival according to timing of immune checkpoint inhibitors administration in patients with advanced cancer: results from a large single-centre cohort analysis
- Central nervous system involvement in acute lymphoblastic leukemia: pathogenesis and targeted therapy
- Overcoming ctDNA MRD Payer Gaps and Operational Hurdles in Bladder Cancer
- Long-term oncologic outcomes of patients with grade group 1 prostate cancer and pT3a disease on final pathology
- DEC-C Plus Venetoclax May Quickly Replace IV HMA Regimens in AML
- Overcoming IGF1R-mediated resistance to oncolytic HSV1 and radiotherapy via triple combination therapy
- OPTIM: a randomized phase II trial of nivolumab followed by nivolumab-ipilimumab or docetaxel at progression in recurrent/metastatic squamous cell carcinoma of the head and neck (OPTIM; AIO-KHT-0117)
Sunday, July 19